Dyslipidemia in Type 2 Diabetes (0767-034)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00547274|
Recruitment Status : Terminated
First Posted : October 22, 2007
Last Update Posted : June 12, 2015
The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type II Dyslipidemia||Drug: MK0767||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||111 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Study Start Date :||July 2003|
|Actual Primary Completion Date :||November 2003|
|Actual Study Completion Date :||November 2003|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00547274
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|